Evotec SE has entered the obesity field under a new partnership with three French institutions where it will identify targets and diagnostic markers for the treatment of metabolic disorders, including over-weight and obesity. This is in response to the prevalence of obesity and the success of the first commercial medicines to treat it. Announced on 30 May, the partnership brings Evotec into an alliance with Inserm, the French National Institute of Health and Medical Research; Lille University Hospital; and Inserm Transfert, a private subsidiary of Inserm.
